Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting: 52-Week Data From the Phase 4 ARTISTYK Study

Main Article Content

Steven R. Feldman
Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Todd Schlesinger
Clinical Research Center of the Carolinas, Charleston, South Carolina, USA

Leon H. Kircik
Icahn School of Medicine at Mt Sinai, NY, New York, USA

Jorge Garcia-Zuazaga
Apex Clinical Research Center, Mayfield Heights, Ohio, USA

Orit Markowitz
OptiSkin Medical, NY, New York, USA

James Del Rosso
Touro University, Henderson, Nevada, and JDR Dermatology Research, Las Vegas, Nevada, USA

Benjamin Lockshin
US Dermatology Partners, Rockville, Maryland, USA

Raja K. Sivamani
Integrative Skin Science and Research, Sacramento, California, USA

Eugene Balagula
Bristol Myers Squibb, Princeton, New Jersey, USA

Andrew Napoli
Bristol Myers Squibb, Princeton, New Jersey, USA

Wei Zhu
Bristol Myers Squibb, Princeton, New Jersey, USA

Anna Begelfer
Bristol Myers Squibb, Princeton, New Jersey, USA

Yogita Kolekar
Bristol Myers Squibb, Princeton, New Jersey, USA

Yichen Zhong
Bristol Myers Squibb, Princeton, New Jersey, USA

April W. Armstrong
University of California Los Angeles, Los Angeles, California, USA

Keywords

Deucravacitinib, quality of life , plaque psoriasis

References

NA

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/7j9e8h28

Article Details

How to Cite
1.
Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting: 52-Week Data From the Phase 4 ARTISTYK Study. J of Skin. 2025;9(6):s649. doi:10.25251/7j9e8h28
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)